News - CeleCor Therapeutics

Rapid zalunfiban treatment at 1st point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications

November 10, 2025

DEL MAR, CALIF., USA – Rapid treatment with CeleCor Therapeutics’ investigational heart-attack drug, zalunfiban, resulted in higher levels of blood flow to the heart and an approximately 21% reduction in a patient’s risk of experiencing a larger MI or one complicated by death, stroke, reinfarction, stent thrombosis or heart failure, new Phase 3 data show.

Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results

September 23, 2025

DEL MAR, CALIF., USA – CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug Disaggpro^TM (zalunfiban) has shown positive primary efficacy and primary safety outcomes.

Celecor Completes Multinational Phase 3 Registrational Study of Novel Anti-Platelet Agent for Heart Attack

May 27, 2025

CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of Disaggpro^TM (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – including before patients reach the hospital.